The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 09, 2024

Filed:

Aug. 24, 2021
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Guochun Gong, Pleasantville, NY (US);

Charleen Hunt, Montvale, NJ (US);

Daisuke Kajimura, Sleepy Hollow, NY (US);

Suzanne Hartford, Putnam Valley, NY (US);

Brian Zambrowicz, Sleepy Hollow, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A01K 67/027 (2006.01); C12Q 1/6897 (2018.01); C12N 15/11 (2006.01); C12N 9/22 (2006.01); A61K 49/00 (2006.01); A61K 9/00 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6897 (2013.01); A01K 67/027 (2013.01); A01K 67/0275 (2013.01); A61K 9/0019 (2013.01); A61K 49/0008 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/907 (2013.01); A01K 2217/072 (2013.01); A01K 2217/15 (2013.01); A01K 2217/206 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01); A01K 2267/0393 (2013.01); C07K 2319/60 (2013.01); C12N 2310/20 (2017.05); C12N 2750/14141 (2013.01); C12N 2800/80 (2013.01); C12Q 2600/106 (2013.01);
Abstract

Methods and compositions are provided herein for assessing CRISPR/Cas-mediated non-homologous end joining (NHEJ) activity and/or CRISPR/Cas-induced recombination of a target genomic locus with an exogenous donor nucleic acid in vivo and ex vivo. The methods and compositions employ cells and non-human animals comprising a Cas expression cassette such as a genomically integrated Cas expression cassette so that the Cas protein can be constitutively available or available in a tissue-specific or temporal-specific manner. Methods and compositions are also provided for making and using these non-human animals, including use of these non-human animals to assess CRISPR/Cas activity in vivo via adeno-associated virus (AAV)-mediated delivery of guide RNAs to the non-human animals.


Find Patent Forward Citations

Loading…